<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03399032</url>
  </required_header>
  <id_info>
    <org_study_id>KE-0254/330/2017</org_study_id>
    <nct_id>NCT03399032</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Caspofungin</brief_title>
  <official_title>Pharmacokinetics of Caspofungin in Critically Ill Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Lublin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Lublin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to describe the pharmacokinetics of standard doses of&#xD;
      caspofungin in critically ill patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective observational study performed on critically ill patients. Inclusion&#xD;
      criteria are: severe sepsis on admission requiring broad-spectrum antibiotics. Both medical&#xD;
      and surgical patients will be included. Any type of infections will be included (pulmonary,&#xD;
      abdominal, urinary tract, etc.) Antibiotics regimen includes: broad spectrum anti-bacterial&#xD;
      antibiotics plus caspofungin (70 mg i.v. on the first day day, and 50 mg i.v. on the&#xD;
      consecutive days, once daily.&#xD;
&#xD;
      Blood samples (3 mL) will be collected 2, 4, 8,12 and 24 hours after each dose of caspofungin&#xD;
      for 3 consecutive days. The standard arterial canula will be used to obtain samples.&#xD;
&#xD;
      30 minutes after each sample collection, blood will be centrifuged for 10 minutes at 3,000&#xD;
      rpms. Subsequently, supernatant will be collected and frozen.&#xD;
&#xD;
      Serum caspofungin concentration will be measured with high performance liquid chromatography.&#xD;
&#xD;
      Each patient's hemodynamics parameters will be recorded with the use of transpulmonary&#xD;
      thermodilution technique (PICCO). Other therapies i.e.: ventilatory support, sedation, an&#xD;
      antifungal agent will be given as required.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">February 5, 2018</start_date>
  <completion_date type="Anticipated">September 3, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 6, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum concentration of caspofungin</measure>
    <time_frame>72 hours for each patient from the tigecycline treatment initiation</time_frame>
    <description>Samples obtain from ICU patients 2, 4, 8 12 and 24hours after each dose of caspofungin for 3 days.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Septic Shock</condition>
  <condition>Fungal Infection</condition>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>Caspofungin</arm_group_label>
    <description>Each patient will receive: caspofungin i.v. once daily ( 70 mg on the first day, 50 mg on the 2 and 3 day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caspofungin</intervention_name>
    <description>Each patient will receive: caspofungin i.v. once daily ( 70 mg on the first day, 50 mg on the 2 and 3 day&#xD;
Blood samples (3 mL) will be collected 2, 4, 8, 12 and 24 hours after each dose of caspofungin for 3 consecutive days.</description>
    <arm_group_label>Caspofungin</arm_group_label>
    <other_name>blood collection</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Patients' arterial blood samples.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to ICU due to severer sepsis recognition. Both medical and surgical&#xD;
        patients will be included. Any site of infection will be treated in the manner.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who require ICU treatment due to severe sepsis age&#xD;
&#xD;
          -  18-80 years&#xD;
&#xD;
          -  an eligible consent obtained from the patient or his/her attendant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  allergy to caspofungin&#xD;
&#xD;
          -  lack of consent to participate in the study&#xD;
&#xD;
          -  age of patients below 18 or above 80 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Michał Borys, M.D., PhD</last_name>
    <phone>+48 506350569</phone>
    <email>michalborys1@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mirosław Czuczwar, M.D., PhD</last_name>
    <phone>+48 509390985</phone>
    <email>czuczwarm@gmail.com</email>
  </overall_contact_backup>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>January 7, 2018</study_first_submitted>
  <study_first_submitted_qc>January 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 16, 2018</study_first_posted>
  <last_update_submitted>January 7, 2018</last_update_submitted>
  <last_update_submitted_qc>January 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Lublin</investigator_affiliation>
    <investigator_full_name>Michał Borys</investigator_full_name>
    <investigator_title>associate professor</investigator_title>
  </responsible_party>
  <keyword>caspofungin</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caspofungin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

